SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10597	Companies
224782	Keywords
153520	Articles
118943	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 05/18/2026 at 21:30, 1 month ago

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD
ElevAATe phase 2 study shows efdoralprin alfa surpassing traditional therapy in achieving and maintaining fAAT levels in AATD patients with emphysema. Results presented at 2026 ATS International Conference

Efdoralprin Alfa ElevAATe FAAT Levels AATD Emphysema
BRIEF

published on 04/24/2026 at 20:35, 1 month 24 days ago

Sanofi Prices €2.3 Billion in Bond Offering

Corporate Finance Bond Issue Sanofi Fixed-rate Notes Euro Medium Term Note
PRESS RELEASE

published on 04/24/2026 at 20:30, 1 month 24 days ago

Press Release: Sanofi successfully prices 2.3 billion of bond issue
Sanofi successfully prices €2.3 billion bond issue with notes across 3 tranches under Euro Medium Term Note programme. Net proceeds for general corporate purposes

Bond Issue Corporate Purposes Sanofi Euro Medium Term Note Global Coordinators
BRIEF

published on 04/24/2026 at 12:14, 1 month 24 days ago

Sanofi's Cenrifki Receives Positive CHMP Opinion for SPMS

Sanofi HERCULES Study CHMP Recommendation Cenrifki Approval SPMS Treatment
BRIEF

published on 04/24/2026 at 12:14, 1 month 24 days ago

Sanofi receives a favorable opinion for tolebrutinib in the treatment of multiple sclerosis

Multiple Sclerosis Approval Sanofi Tolebrutinib CMUH
PRESS RELEASE

published on 04/24/2026 at 12:09, 1 month 24 days ago

Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
CHMP recommends EU approval for Sanofi's Cenrifki (tolebrutinib) to treat secondary progressive multiple sclerosis without relapses. Positive opinion based on HERCULES phase 3 study

Multiple Sclerosis Sanofi CHMP Tolebrutinib Cenrifki
BRIEF

published on 04/22/2026 at 23:35, 1 month 25 days ago

Sanofi and Regeneron Win FDA Approval for Dupixent in Young Children

FDA Approval Sanofi Dupixent Regeneron Pediatric Medicine
PRESS RELEASE

published on 04/22/2026 at 23:30, 1 month 25 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as first biologic medicine for young children with uncontrolled chronic spontaneous urticaria, expanding previous approval for adults and adolescents

Sanofi Dupixent CSU Regeneron Biologic Medicine
BRIEF

published on 04/18/2026 at 12:05, 2 months ago

Sanofi's Nuvaxovid demonstrates better tolerability compared to mNEXSPIKE

Sanofi Tolérance Nuvaxovid ESCMID COVID-19 Vaccination
BRIEF

published on 04/18/2026 at 12:05, 2 months ago

Sanofi's Vaccine Shows Superior Tolerability in Recent Study

COVID-19 Sanofi Nuvaxovid Vaccine Study Tolerability

Accesswire

Published on 06/18/2026 at 18:00, 3 hours 55 minutes ago

BEACN Closes Second Series Under Loan Program and Previews BEACN App Version 1.4
Published on 06/18/2026 at 17:30, 4 hours 25 minutes ago

Sekur Private Data Appoints Nathan R. Price as Special Advisor for Diplomacy & Intelligence
Published on 06/18/2026 at 15:50, 6 hours 5 minutes ago

Pentagon I Capital Corp. and Prospectiva Resources Ltd. Announce Financing
Published on 06/18/2026 at 15:00, 6 hours 55 minutes ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
Published on 06/18/2026 at 14:30, 7 hours 25 minutes ago

Voting Results from Solitario Resources Corp Annual Meeting Held June 17, 2026

View all ACCESSWIRE

EQS Group

Published on 06/18/2026 at 18:55, 2 hours 59 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:55, 2 hours 59 minutes ago

Holding(s) in Company
Published on 06/18/2026 at 18:30, 3 hours 24 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/18/2026 at 18:25, 3 hours 29 minutes ago

Sopra Steria achives Level 2 Responsible Digital Label and strengthens its responsible digital strategy
Published on 06/18/2026 at 17:45, 4 hours 9 minutes ago

2CRSi SA: 2CRSi disputes the content of the document published by Grizzly Research and is preparing a substantiated response calling for the suspension of trading in its shares

Les Echos

Published on 06/18/2026 at 18:00, 3 hours 55 minutes ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 4 hours 10 minutes ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 4 hours 16 minutes ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026
Published on 06/18/2026 at 13:00, 8 hours 54 minutes ago

Edenred statement
Published on 06/18/2026 at 09:06, 12 hours 48 minutes ago

Eiffage, member of the NSORe joint venture, wins the contract for a converter station for the NSC2 offshore grid connection project in Germany

View all LES ECHOS COMFI WIRE